\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPRO	IVAL
OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

1. Name and Addres DUNN JOHN	s of Reporting Perso	n*	2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) 14 CAMBRIDG	(Last) (First) (Middle) 14 CAMBRIDGE CENTER		3. Date of Earliest Transaction (Month/Day/Year) 07/21/2008	Х	Officer (give title below) EVP, New Ver	Other (specify below) ntures			
(Street) CAMBRIDGE MA 02142		02142	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)			Peison				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Table I - No	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction D					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)		
Common Stock	07/21/2008		M ⁽¹⁾		6,485	A	\$4,350	31,473.4015 ⁽²⁾	D			
Common Stock	07/21/2008		S ⁽¹⁾		6,485	D	\$67.5	24,988.4015	D			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$43.5	07/21/2008		M ⁽¹⁾			6,485	(3)	02/06/2014	Common Stock	6,485	\$0.00 ⁽⁴⁾	6,485	D	

Explanation of Responses:

1. Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

2. Includes 26.2089 shares acquired under the Biogen Idec Inc. employee stock purchase plan on 6/30/2008.

3. The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/06/04.

4. Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d).

Remarks:

Robert A. Licht, Attorney in Fact for John M. Dunn

** Signature of Reporting Person

07/22/2008

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.